Mylan Will Remain Independent, Board Says In Rejecting Icahn Buy-Out

A response to Icahn's proposed $5.4 bil. bid appears to shut the door to potential "white knight" pharma company suitors that were invited through Icahn's offer. Mylan does not consider Icahn's bid "serious"; in response, High River says it would put $1.5 bil. in equity into the deal.